The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Marta Boffito

St. Stephen's Centre

Chelsea and Westminster Hospital

369 Fulham Road

London SW10 9NH

United Kingdom

[email]@chelwest.nhs.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom. 2004 - 2011
  • St Stephens Aids Trust, Crusaid Research Institute, St Stephen's Centre, London, UK. 2008
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. 2004

References

  1. Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., Seymour, N., Gazzard, B., Moyle, G. Antimicrob. Agents Chemother. (2011) [Pubmed]
  2. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. Boffito, M., Jackson, A., Lamorde, M., Back, D., Watson, V., Taylor, J., Waters, L., Asboe, D., Gazzard, B., Pozniak, A. J. Acquir. Immune Defic. Syndr. (2009) [Pubmed]
  3. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., Pozniak, A., Gazzard, B., Moyle, G. Antivir. Ther. (Lond.) (2008) [Pubmed]
  4. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. Boffito, M., Miralles, D., Hill, A. HIV. Clin. Trials (2008) [Pubmed]
  5. A review of the clinical pharmacology of maraviroc. Introduction. Boffito, M., Abel, S. Br. J. Clin. Pharmacol (2008) [Pubmed]
  6. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. Boffito, M., Winston, A., Jackson, A., Fletcher, C., Pozniak, A., Nelson, M., Moyle, G., Tolowinska, I., Hoetelmans, R., Miralles, D., Gazzard, B. AIDS (2007) [Pubmed]
  7. Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy. Boffito, M. New Microbiol. (2007) [Pubmed]
  8. Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Boffito, M., Pillay, D., Wilkins, E. Int. J. Clin. Pract. (2006) [Pubmed]
  9. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Boffito, M., Back, D., Stainsby-Tron, M., Hill, A., Di Perri, G., Moyle, G., Nelson, M., Tomkins, J., Gazzard, B., Pozniak, A. Br. J. Clin. Pharmacol (2005) [Pubmed]
  10. The pharmacokinetics of HIV protease inhibitor combinations. Boffito, M., Maitland, D., Samarasinghe, Y., Pozniak, A. Curr. Opin. Infect. Dis. (2005) [Pubmed]
  11. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. Boffito, M., Maitland, D., Dickinson, L., Back, D., Hill, A., Fletcher, C., Moyle, G., Nelson, M., Gazzard, B., Pozniak, A. J. Antimicrob. Chemother. (2005) [Pubmed]
  12. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Boffito, M., Acosta, E., Burger, D., Fletcher, C.V., Flexner, C., Garaffo, R., Gatti, G., Kurowski, M., Perno, C.F., Peytavin, G., Regazzi, M., Back, D. Antivir. Ther. (Lond.) (2005) [Pubmed]
  13. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Boffito, M., Acosta, E., Burger, D., Fletcher, C.V., Flexner, C., Garaffo, R., Gatti, G., Kurowski, M., Perno, C.F., Peytavin, G., Regazzi, M., Back, D. Antivir. Ther. (Lond.) (2005) [Pubmed]
  14. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Boffito, M., Pozniak, A., Kearney, B.P., Higgs, C., Mathias, A., Zhong, L., Shah, J. Antimicrob. Agents Chemother. (2005) [Pubmed]
  15. Host determinants of antiretroviral drug activity. Boffito, M., Winston, A., Owen, A. Curr. Opin. Infect. Dis. (2005) [Pubmed]
  16. Lopinavir protein binding in vivo through the 12-hour dosing interval. Boffito, M., Hoggard, P.G., Lindup, W.E., Bonora, S., Sinicco, A., Khoo, S.H., Di Perri, G., Back, D.J. Ther. Drug. Monit (2004) [Pubmed]
  17. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., Higgs, C., Fletcher, C., Mandalia, S., Gazzard, B., Pozniak, A. Antivir. Ther. (Lond.) (2004) [Pubmed]
  18. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. Boffito, M., Kurowski, M., Kruse, G., Hill, A., Benzie, A.A., Nelson, M.R., Moyle, G.J., Gazzard, B.G., Pozniak, A.L. AIDS (2004) [Pubmed]
  19. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. Boffito, M., Dickinson, L., Hill, A., Back, D., Moyle, G., Nelson, M., Higgs, C., Fletcher, C., Gazzard, B., Pozniak, A. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
 
WikiGenes - Universities